Prosecution Insights
Last updated: November 20, 2026

Viiv Healthcare UK (No 3) Limited

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Viiv Healthcare UK (No 3) Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner, KASSA, TIGABU, who is the busiest examiner with 1 pending office action. The prosecution is currently concentrated in 1 distinct art unit, indicating a focused technical scope for this pending application. This concentration allows for a dedicated strategy tailored to the specific requirements of the sector.

With only the 1 pending office action and a distinct examiner involved, the company's current interaction with the USPTO is centralized. Practitioners can focus their resources on the specific expectations of KASSA, TIGABU and the guidelines of the distinct art unit. This approach ensures that the company's current intellectual property efforts are directed toward a well-defined goal. The presence of the pending action indicates a precise footprint in the current patent landscape.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KASSA, TIGABU 1 36.6% +27.7%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
19339458 PHARMACEUTICAL COMPOSITIONS KASSA, TIGABU —

Top Art Units

Art UnitApps
1619 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19339458 PHARMACEUTICAL COMPOSITIONS KASSA, TIGABU 1619 §103 Final Rejection — Pending Sep 25, 2025

Managing Viiv Healthcare UK (No 3) Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Viiv Healthcare UK (No 3) Limited have?

Viiv Healthcare UK (No 3) Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Viiv Healthcare UK (No 3) Limited applications?

Tigabu Kassa has the most, with 1 of Viiv Healthcare UK (No 3) Limited's pending office actions.

What technology area are Viiv Healthcare UK (No 3) Limited's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month